Chas - thanks. You brought up this piece of information that is new to me. "... the niche (trigs >500) indication that does not exist in Europe" Does it mean European clinical practice doesn't consider patients with TG > 500 as its own distinct population as the US practice does?
If so, then it makes sense to me that Amarin never filed Marine patents in EU, and neither did it apply for Marine indications to EMA. EU is just a RIT market. If analysts only give $2 to $4 per share to the OUS market in the event of an appeal loss and the fact that the company's EU GIA announcement moved no needle on the share price, then WS either thinks the Marine patent invalidation will affect its ReduceIt patents somehow, or generic Vascepa may find a way to EU regardless.
Market Data 
Markets 
AI
